Samsung Biologics has made a $1.8 billion all-cash offer to acquire Switzerland's PolyPeptide Group, a leader in peptide-based pharmaceutical ingredients. This acquisition aims to diversify Samsung's portfolio by entering the fast-growing peptide therapeutics market, especially targeting obesity and diabetes treatments like GLP-1 drugs. The deal, expected to close by year-end, is the largest biopharmaceutical M&A in South Korea's history and will expand Samsung's global reach with PolyPeptide's facilities in Europe, the US, and India. This move positions Samsung Biologics to meet rising demand for innovative weight-loss and diabetes therapies.
Sterling Infrastructure reported a 90% increase in Q2 revenue to $1.17 billion, largely fueled by its E-Infrastructure Solutions segment, which now accounts for 78% of revenue and grew 192% year-over-year. Adjusted EBITDA rose 104% to $256.7 million,...
A trader on Hyperliquid opened a massive 40x leveraged long position of 911.55 BTC worth about $70 million at an average price of $77,733. The liquidation price is $76,308.60, and Bitcoin's current price near $77,150 leaves less than 1% room before t...
The Iran-backed Houthi militant group has taken control of Yemen's strategic Red Sea port city of Mokha, near the critical Bab el-Mandeb Strait. This move threatens global shipping lanes and increases pressure on oil supply routes, contributing to oi...
Capricor Therapeutics faces a class action lawsuit alleging it made false statements about the progress of its deramiocel drug candidate toward FDA approval. The lawsuit claims the company misled investors by promoting positive trial results while kn...
Lumen Research rates the iShares MSCI Global Silver and Metals Miners ETF (SLVP) as Buy, citing strong earnings leverage to rising silver prices and robust margins in Q2. In contrast, the Kurv Silver Enhanced Income ETF (KSLV) is rated Hold because i...
